KALV KalVista Pharmaceuticals, Inc.
Healthcare$26.81+0.07%ClosedMarket Cap: $1.43B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
-499.39
P/S
12.31
EV/EBITDA
-11.36
DCF Value
$47.88
FCF Yield
-1.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
92.0%
Operating Margin
-120.8%
Net Margin
-119.4%
ROE
-1057.4%
ROA
-41.3%
ROIC
-46.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q3 null | $59.9M | 93.4% | $-11.5M | $-5.4M | $— | — |
| Q3 null | $59.9M | 90.4% | $-13.3M | $-5.4M | $— | — |
| Q4 null | $40.9M | 91.6% | $-23.4M | $-23.5M | $— | — |
| Q3 null | $59.9M | 90.4% | $-13.3M | $-5.4M | $— | — |
| FY null | $73.6M | 91.7% | $-171.8M | $-164.3M | $— | — |
| Q2 null | $13.7M | 91.0% | $-46.0M | $-49.5M | $— | — |
| Q1 null | $1.4M | 58.6% | $-59.0M | $-60.1M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-55.0M | $-52.2M | $— | — |
| FY null | $0.00 | NaN% | $-188.0M | $-183.4M | $— | — |
| Q3 null | $0.00 | NaN% | $-42.9M | $-48.5M | $— | — |
| Q2 null | $0.00 | NaN% | $-45.8M | $-42.3M | $— | — |
| Q1 null | $0.00 | NaN% | $-44.2M | $-40.4M | $— | — |